Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) vs F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)
This oral reports the prespecified primary and updated (for overall survival) analysis of VERONICA (NCT03584009), a Phase II study of venetoclax + fulvestrant vs. fulvestrant alone in estrogen receptor-positive, HER2-negative, post-cyclin-dependent kinase 4/6 inhibitor therapy locally advanced, or metastatic breast cancer. The primary endpoint was clinical benefit rate (complete response, partial response or stable disease ≥24 weeks); other endpoints included progression-free survival, overall survival, objective response rate, duration of response, safety and tolerability, and exploratory biomarker analysis.